GRFS News and Press, Grifols S.A. From 02/07/22

There could be a downside to the consensus revenue and margins of Grifols (GRFS -4.0%) (OTCPK:GIKLY) (OTCPK:GIFLF), JPMorgan analyst James D Gordon warned, issuing the firm’s earnings preview for the Spanish plasma maker on Monday. After the comments, Grifols (NASDAQ:GRFS) ADRs have re...

Repro Med Systems (NASDAQ:KRMD) has added ~6.5% in the post-market after announcing the FDA 510(k) clearance for FREEDOM60 Infusion System that would expand its on-label use. Therefore, FREEDOM60 is now authorized for use in two additional subcutaneous immunoglobulin (SCIg...

Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma - The new Biomat USA plasma donor center, located at UMass Chan Medical School campus in Worcester, Mass., is Grifols' first donor center in the state and secon...

Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the longer-term growth outlook. With the valuation discount to CSL widening to unwa...

The following slide deck was published by Grifols, S.A. in conjunction with this event. For further details see: Grifols presents at 2021 investor and analyst day - slideshow

Grifols ([[GRFS]] -4.2%) forecasts new product sales to make up about one fifth of the company's total revenue by 2030.The company, in its investor presentation slides as part of its analyst day, forecast revenue from new product launches to grow to 20% of its total topline by 2030, up from a...

Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B - The new formulation delivers anti-hepatitis B virus antibodies using a unique and sophisticated caprylate chromatography process - Grifols ...

Grifols (GRFS) shares rise 3% during premarket trading after signing an agreement with the government of Andorra through Andorra Development and Investment ((ADI)) to establish a global R+D+i hub to advance knowledge of the human immune system and investigate and develop n...

Grifols operates in the very attractive and lucrative plasma business. The plasma-supply chain has been disrupted by the pandemic but the situation should normalize with the vaccination. Even though some new medicines could potentially disrupt the market, we believe related fears ...

Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 PR Newswire BARCELONA, Spain , April 9, 2021 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report ...